pharma · Fatty Liver · Inflammatory Disease · GLMD
Galmed Pharmaceuticals
Galmed Pharmaceuticals clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 16 Ze’ev Tiomkin Street, Tel Aviv, 6578317, IL, USA
- Founded
- 2000
- Employees
- 10
- Programs
- 13
- Drugs
- 5
- Patents
- 11
Galmed Pharmaceuticals projects
5 ClinicalTrials.gov programs sponsored by Galmed Pharmaceuticals.
Galmed Pharmaceuticals has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Aramchol
Galmed Pharmaceuticals
Fatty Liver
1 trial -
Aramchol
Galmed Pharmaceuticals
Gallstones
1 trial -
Aramchol
Galmed Pharmaceuticals
Non-Alcoholic Fatty Liver Disease
1 trial -
Aramchol meglumine
Galmed Pharmaceuticals
Primary Sclerosing Cholangitis
1 trial -
mFOLFOX6 + BIBF 1120
Galmed Pharmaceuticals
Colorectal Cancer
1 trial
Frequently asked questions
How many clinical projects does Galmed Pharmaceuticals have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.